

February 09, 2024

Ref:- GHL/2023-24/EXCH/101

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

Scrip Code: 543654 Symbol: MEDANTA

Sub: Newspaper Publication - Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2023

Dear Sir(s)/Madam,

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith, the copies of Newspaper clippings of the Unaudited Financial Results of the Company, for the Quarter and Nine Months ended December 31, 2023, published in Financial Express (English) and Jansatta (Hindi) on Friday, February 09, 2024.

This is for your information and record.

Thanking You,

For Global Health Limited

Rahul Ranjan Company Secretary & Compliance Officer M. No. A17035

Encl: a/a













FINANCIAL EXPRESS

be mailed. It is clarified that all the Public Shareholders (registered or unregistered) are eligible to participate in this offer at any time prior to the closure of tendering period. VIII PROCEDURE FOR TENDERING OF SHARES IN THE CASE OF NON-RECEIPT OF LETTER OF OFFER

*The Identified Date is only for the purpose of determining the Public Shareholders as on such date to whom the letter of offer would

All the shareholders, whether holding the equity shares in physical form or dematerialized form or holding lock in equity shares are eligible to participate in this offer at any time during the tendering period for this offer. Persons who have acquired equity shares but whose names do not appear in the register of members of the Target Company

on the Identified Date, or unregistered owners or those who have acquired equity shares after the Identified Date, or those

- who have not received the letter of offer, may also participate in this offer. The open offer will be implemented by the Acquirers through a stock exchange mechanism made available by stock exchanges in the form of separate window ("Acquisition Window"), as provided under the SEBI (SAST) Regulations and SEBI Circular number CIR/CFD/POLICYCELL/1/2015 dated 13th April, 2015 read with SEBI Circular number CFD/DCR2/ CIR/P/2016/131 dated 9th December, 2016 as may be amended from time to time, issued by SEBI.
- BSE shall be the designated stock exchange for the purpose of tendering equity shares in the open offer
- The Acquirer has appointed M/s Mansukh Securities & Finance Limited as the registered broker ("Acquirer's Broker") through whom the purchases and settlements on account of open-offer would be made by the Acquirers.

The Contact details of the Acquirer's Broker are as follows:

Mansukh Securities & Finance Limited, Address: Mansukh House, 6, Pandav Nagar, Delhi-110092

Contact Person: Mr. Virender Mansukhani Tel No.: +91-11-47617800/61287800

Email Id: contact@mansukh.com

- All shareholders who desire to tender their equity shares under the open offer would have to intimate their respective stock brokers ("Selling Broker") within the normal trading hours of the secondary market, during the tendering period.
- Such equity shares would be transferred to the respective Selling Broker's pool accounts prior to placing the bid A separate acquisition window will be provided by the stock exchange to facilitate placing of sell orders. The Selling Broker can enter orders for dematerialized as well as physical equity shares.
- The detailed procedure for tendering the equity shares in this offer will be available in the letter of offer
- In accordance with the Frequently Asked Questions issued by SEBI, "FAQs" -Tendering of Physical Shares in Buy Back Offer/Open Offer/Exit Offer/Delisting" dated 20th February, 2020. SEBI Circular No. SEBI/HO/CFD/CMD1/CIRP/2020/144 dated 31st July, 2020 and BSE Notice No. 20200528-32 dated 28th May, 2020, shareholders holding securities in physical forms are allowed to tender shares in open offer. However, such tendering shall be as per provisions of SEBI (SAST) Regulations, 2011.

Other Information

IX

- The Acquirers accept full responsibility for the information contained in the Public Announcement and this Detailed Public Statement (other than such information that has been sourced from public sources or provided and confirmed by the Target Company and shall be jointly or severally responsible for the fulfillment of the obligations under the offer and as laid down in SEBI (SAST) Regulations.
- The Acquirers has appointed M/s Beetal Financial & Computer Services Pvt. Ltd, as a Registrar to the Offer having its office at Beetal House, 3rd Floor, 99, Madangir, Behind LSC, New Delhi-110062 ("Registrar to the Offer") E-Mail: beetalrta@gmail.com, Tel. Nos.: 29961281-82, Fax No.: 29961284, Contact Person: Mr. Punit Mittal.
 - This Detailed Public Statement and the Public Announcement would also be available on SEBI's Website (www.sebi.gov.in). The Acquirers reserves the right to withdraw the offer pursuant to Regulation 23(1) of the SEBI (SAST) Regulations. Any such

withdrawal will be notified in the form of a Public Announcement in the same newspapers in which this Detailed Public Statement appears.

D & A FINANCIAL SERVICES (P) LIMITED 13, Community Centre, East of Kailash, New Delhi - 110065.

Tel nos.: 011-41326121, 40167038; Email: investors@dnafinserv.com Contact Person: Mr. Priyaranjan/Ms. Radhika Pushkarna SEBI Reg. No.: INM000011484

Manager to the Offer

Beetal Financial & Computer Services

Registrar to the Issue

Pvt. Limited Beetal House, 3rd Floor, 99, Madangir, Near Dada Harsukh Das Mandir. New Delhi-110062 E. Mail: beetalrta@gmail.com Tel. Nos.: 29961281-82, Fax No.: 29961284 Contact Person: Mr. Punit Mittal. SEBI Reg. No.: INR000000262

Issued on behalf of the Acquirers by Manager to the Offer

Place: New Delhi Date: 08.02.2024

SOM DATT FINANCE CORPORATION LIMITED

CIN: L65921DL1993PLC377542 Registered Address: 516, Suneja Tower-I, District Centre, Janakpuri, Delhi - 110058 STATEMENT OF UNAUDITED FINANCIALS RESULTS FOR THE QUARTER AND NINE MONTH ENDED DECEMBER 31, 2023

(All amounts are in INR lacs, except otherwise stated)

		Quarter ended			9 Month	Year ended	
	Particulars	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
	Faruculais	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(i (ii	venue from operations) Interest income) Dividend income) Net gain on fair value changes	1.23 12.39 435.76	0.46 14.35 347.11	7.93 254.21	1.69 30,47 1,108.46	20.05 144.10	27.98 106.45
1	Total revenue from operations	449.38	361.92	262.14	1,140.62	164.15	134.43
H	Other income	172)	7/2)	172)	, A	0.05	0.05
m	Total income (I+II)	449.38	361.92	262.14	1,140.62	164.20	134.48
(i) (ii) (iv)	penses) Finance cost) Fees and commision expense) Employee benefits expense) Depreciation and amortization expense) Other expenses	1.22 34.97 0.27 8.74	1.82 13.27 0.26 10.17	1.16 4.24 0.25 9.87	4.26 53.49 0.79 24.70	3.46 17.99 0.71 20.76	4.60 22.58 0.99 25.50
iv	Total expenses	45.20	25.52	15.52	83.24	42.92	53.67
v	Profit before exceptional items and tax (III-IV)	404.18	336.40	246.62	1,057.39	121.28	80.81
VI	Exceptional items		- 2	- 4	1		
VII	Profit before tax (V-VI)	404.18	336.40	246.62	1,057.39	121.28	80.81
(i) (ii) (iv)	c expenses) Current tax) MAT Credit Entitlement) Adjustment of tax relating to earlier years) Deferred tax	184.86 (184.86) 0.06 48.44	36.15	37.44	184.86 (184.86) 0.06 121.10	0.06 13.41	13.56 (13.56) 0.99 7.75
	Total tax expenses	48.50	36.15	37.44	121.17	13.47	8.74
	Profit for the period (VII-VIII)	355.68	300.26	209.18	936.22	107.81	72.07
(i	ner comprehensive income) Items that will not be reclassified to profit or loss in subsequent years: - Remeasurement of post employment benefit obligations) Income tax relating to items that will not be reclassified to profit or loss	(4					0.01
X	Total other comprehensive income	112	1145	102	9	. 2	0.01
XI	Total comprehensive income for the period (IX+X)	355.68	300.26	209.18	936.22	107.81	72.08
()	sic / Diluted Earnings Per Share (FV of INR 10/- each)) Basic) Diluted	3.55 3.55	3.00 3.00	2.09 2.09	9.35 9.35	1.08 1.08	0.72 0.72

See accompanying notes to financial results. NOTES:

The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 8th Feb 2024. The Statutory Auditors of the Company have carried out a limited review of the aforesaid results, pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India and in accordance with the circulars, guidelines and directions issued by the Reserve Bank of India (RBI) from time to time. The Company is engaged primarily in NBFC business. As per Indian Accounting Standards (IndAs) 108 "Operating Segment", the

company's business falls within a single business segment. (a) Pursuant to Share Purchase Agreement (SPA) dated November 09, 2022, executed between Mrs. Vijay Rathee and Mr. Kuldeep

Singh Rathee ("Seller/ outgoing promoter") and Dr. Bhaskara Rao Bollineni and Mr. Bhavanam Ruthvik Reddy ("Acquirer/ New

Promoter") and public announcement dated November 09, 2022, made by Acquirer in terms of (Substantial Acquisition of Shares and Takeover) Regulation 2011, Acquirer have acquired 69,41,050 equity shares (representing 69,36% of the total equity Capital of the Company) it includes 69,39,650 equity shares held by the outgoing promoter. SPA was consummated at the Board Meeting held on July (b) Further, according to the consummation of SPA, the Board at its meeting held on July 21, 2023, subject to approval of shareholders had appointed Dr. Bhaskara Rao Bollineni (Non-Executive), Mr. Bhavanam Ruthvik Reddy (Executive), and Mr. Veera Venkata Subba Rao Meka (Executive) as Additional Directors of the Company, subsequently at the Board Meeting held on September 12, 2023, Mr. Bhavanam Ruthvik Reddy was appointed as Chief Executive Director and Whole Time Director for 3 years effective from September 12, 2023, Mr. Veera Venkata Subba Rao Meka was appointed as Managing Director for 3 years effective from September 12, 2023 and Ms. Jayanthi Talluri was appointed as Independent (Women) Director for 2 years effective from September 12, 2023. The said appointments

were approved by the shareholders of the Company through postal ballot vide resolutions dated October 19, 2023. (c) Application for reclassification of Promoters i.e to reclassify (a) "outgoing promoters i.e Mrs. Vijay Rathee and Mr. Kuldeep Singh Rathee) as Public" and (b) "Dr. Bhaskara Rao Bollineni and Mr. Bhavanam Ruthvik Reddy as the Promoter" of the Company is pending for approval before Bombay Stock Exchange: Figures for the previous quarters/periods have been regrouped/reclassified, wherever necessary, to correspond with the current

period's classifications/disclosures. There are minor rounding-off variances as figures are converted into lacs.

For and on behalf of board of directors of Som Datt Finance Corporation Limited Veeravenkata Subba Rao Meka

Place: Hyderabad Managing Director Date: February 08, 2024 DIN: 07173955



Global Health Limited (formerly known as Global Health Private Limited)

CIN: L85110DL2004PLC128319

Read. Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi 110024, India Corp. Office: Medanta - The Medicity, Sector - 38, Gurugram, Haryana 122001, India Tel: +91 124 483 4060 | E-mail: compliance@medanta.org | Website: https://www.medanta.org

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2023

(₹ in Lakhs except EPS)

SI. No.	Particulars	Quarter ended 31.12.2023	Nine months period ended 31.12.2023	
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total income from operations	85,453.28	251,372.12	70,622.60
2	Net profit for the period (before tax and exceptional items)	17,236.47	48,401.08	11,244.94
3	Net profit for the period before tax (after exceptional items)	17,236.47	48,401.08	11,244.94
4	Net profit for the period after tax (after exceptional items)	12,354.07	35,071.18	8,061.38
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	12,406.07	34,978.22	8,087.52
6	Paid up equity share capital	5,368.55	5,368.55	5,363.70
7	Reserves (excluding Revaluation Reserve)*			
8	Earnings Per Share (of ₹ 2/- each) -			
	Basic:	4.61	13.07	3.08
	Diluted:	4.60	13.06	3.08

* Reserves (excluding Revaluation Reserve) as on 31 March 2023 was ₹ 2,37,456.92 Lakhs.

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS

SI. No.	Particulars	Quarter ended 31.12.2023	Nine months period ended 31.12.2023		
		(Unaudited)	(Unaudited)	(Unaudited)	
1	Total income from operations	58,751.10	177,168.33	50,230.89	
2	Net profit for the period (before tax and exceptional items)	12,087.21	36,350.32	7,989.37	
3	Net profit for the period before tax (after exceptional items)	12,087.21	36,350.32	7,989.37	
4	Net profit for the period after tax (after exceptional items)	8,734.40	26,865.15	5,877.26	
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	8,777.17	26,760.24	5,893.01	

Notes:

- 1. These results have been reviewed and recommended by the Audit Committee and accordingly approved by the Board of Directors of the Company at their respective meetings held on 8 February 2024. The result have been subjected to the limited review by the statutory auditors of the Company.
- 2. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the consolidated and standalone Quarter/Annual Financial Results are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and also available at the company's website https://www.medanta.org.

By order of the Board for Global Health Limited

Dr. Naresh Trehan Chairman and Managing Director **VEEJAY LAKSHMI ENGINEERING WORKS LIMITED** Regd. Office: Sengalipalayam, NGGO Colony P.O., Coimbatore 641022 Email Id:compsec@veejaylakshmi.com Website: www.veejaylakshmi.com CIN:L29191TZ1974PLC000705

STATEMENT OF UNAUDITED RESULTS FOR QUARTER/NINE MONTHS PERIOD ENDED 31/12/2023 Rs. in lakhs **PARTICULARS** STANDALONE CONSOLIDATED Year to Year to Year Year to Year Year to Quarter Ended Quarter Ended Ended Ended date upto date upto date upto | date upto 31/12/2023 30/9/2023 31/12/2022 31/12/2023 31/12/2023 31/12/2023 31/12/2023 31/12/2023 31/12/2023 31/12/2023 31/12/2022 31/3/2023 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Total Income from Operations 2128.58 2489.03 1384.85 6497.90 5288.42 6397.19 2128.58 2489.03 1384.85 6497.90 5288.42 6397.19 2 Net Profit/(Loss) before tax -315.90-529.50 -132.27-315.90 -1404.30 (before exceptional and/or extra ordinary items) -130.15-132.27-1252.89 -1404.30-130.15-529.501252.89 3 Net Profit/(Loss) before tax -315.90 -1404.30(after exceptional and/or extra ordinary items) -130.15-132.27 -529.50 -1252.89 -1404.30-130.15-132.27-315.90 -529.50-1252.89Net Profit/(Loss) for the period after tax (after -1404.04 exceptional and or extra ordinary items) -133.31-124.10-317.80-512.73-1241.31 -1404.04 -133.31-124.10-317.80 -512.73 -1241.31 Total Comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) -1211.28 1400.25 -322.75-469.22 -328.031219.41 -141.52-102.881403.34 -144.63and other Comprehensive income (after tax) (Face value of Rs.10/- per share) 507.19 507.19 507.19 507.19 507.19 507.19 507.19 507.19 507.19 507.19 507.19 507.19 Reserves (excluding revaluation reserves as shown in the Audited Balance sheet of previous year) 1891.49 0.00 0.00 0.00 0.00 1738.50 0.00 0.00 0.00 Earnings per share (before extra ordinary items) (of Rs.10/-) each (Not annualised) -2.63-2.45 -6.27-10.11-24.47 -27.68-2.63-2.45-6.27-10.11-24.47 -27.68 -10.11-2.63-2.45 -6.27-24.47 -27.68-2.63-2.45-6.27-10.11-24.47 -27.68 9 Earnings per share (after extra ordinary items) -27.68 (of Rs. 10/-) each (Not annualised) -2.63-2.45-6.27-10.11-24.47 -27.68-2.63-2.45-6.27-10.11-24.47-2.63 -2.45 -10.11-24.47 -27.68 -2.63-10.11 -24.47 -27.68 -6.27-2.45-6.27

Place: Coimbatore

Basic :

Diluted:

Basic :

Equity Share Capital

Date: 08.02.2024 filed with the Stock Exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial -results for the Quarter/Nine months ended 31st December, 2023 are available on the Company website, www.veejaylakshmi.com and on the stock exchange website, www.bseindia.com

Note: The above is an extract of the detailed format of results for the Quarter/Nine months ended 31st December, 2023

NEULAND LABORATORIES LIMITED (CIN: L85195TG1984PLC004393)

For Veejay Lakshmi Engineering Works Limited

(Sd/-) V.J.JAYARAMAN

Chairman

Regd. Office: 11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2023 (Amount in lakhs of ₹, unless otherwise stated)

Quarter Ended Quarter Ended Nine Months Ended Nine Months Ended Year Ended Particulars No. 31.12.2023 30.09.2023 31.12.2022 31.12.2023 31.12.2022 31.03.2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 39,492.89 42,079.64 118,075.81 78,580.94 120,094.62 Total Income 27,018.31 Net profit for the period before tax 10,448.10 12,159.40 3,893.51 30,923.45 10,558.28 21,574.64 Net profit for the period after tax 3 8,139.02 8,924.78 3,054.82 23,251.70 16,351.76 7,897.37 4 Total comprehensive income for the period 8,147.27 8,965.06 2,900.67 23,298.80 7,756.64 16,001.06 5 Paid-up Equity Share Capital 1,290.05 (Face value - ₹10 each) 1,290.05 1,290.05 1,290.05 1,290.05 1,290.05 Other equity (excluding revaluation reserves) as shown in the audited balance sheet 98,035.71 Earnings Per Share (of ₹10 each) (In absolute ₹ terms) 63.44 69.56 23.81 181.23 61.55 127.45 (a) Basic (b) Diluted 69.56 23.81 181.23 61.55 127.45 63.44

Note 1: The financial results for the guarter and nine months ended 31 Dec 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 8th February 2024. Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 31.12.2023 (Unaudited)	Quarter Ended 31.09.2023 (Unaudited)	Quarter Ended 31,12,2022 (Unaudited)	Nine Months Ended 31.12.2023 (Unaudited)	Nine Months Ended 31.12.2022 (Unaudited)	Year Ended 31.03.2023 (Audited)
Total Income	39,492.89	42,079.64	27,018.31	118,075.81	78,580.94	120,094.61
Net profit for the period before tax	10,378.00	12,140.42	3,879.58	30,868.83	10,519.03	21,521.29
Net profit for the period after tax	8,070.12	8,906.41	3,043.63	23,198.90	7,860.89	16,311.92

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

Dr. D.R.Rao

P.V.ABINAV RAMASUBRAMANIAM RAJA

For and on behalf of the Board of Directors

Date: 8th February 2024

Place: Hyderabad

Executive Chairman (DIN 00107737)

Ramco Industries Limited Regd. Office: 47, P.S.K.Nagar, Rajapalayam 626 108.

Corporate Office: "Auras Corporate Centre", 98-A, Dr. Radhakrishnan Road, Mylapore, Chennai - 600 004.

CIN: L26943TN1965PLC005297; WEBSITE: www.ramcoindltd.com

Rs. In Lakhs EXTRACT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS PERIOD ENDED 31.12.2023 Quarter Ended Nine Months Ended Year Ended

17		4	4	<u></u>	(i)	Line India	
	Particulars	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
,		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from Operations	33,363	31,582	30,444	1,13,641	1,10,752	1,45,75
2	Net Profit/(loss) for the period (before tax, Exceptional and /or Extraordinary items)	2,029	1,750	160	8,053	9,605	11,86
3	Net Profit/(loss) for the period (before tax, after Exceptional and /or Extraordinary items)	2,029	1,750	240	8,053	9,685	12,16
4	Net Profit / (Loss) for the period (after tax, after Exceptional and / or Extraordinary items)	1,292	766	4	5,329	6,321	10,61
5	Share of Net profit After Tax (PAT) of Associates accounted for using the equity method	1,346	(1,181)	80	851	87	1,63
6	Total Comprehensive Income for the period (Comprising Net Profit for the period after tax and other Comprehensive Income after tax)	2,536	7,026	807	13,655	7,309	13,1
7	Paid up Equity share capital	835	836	835	835	835	83
8	Other Equity						3,87,5
9	Net worth						3,88,3
10	Earnings Per share of Re.1/- each (Rs.) (Not annualised)						
	Basic :	3.16	(0.50)	0.10	7.40	7.67	14.
534	Diluted :	3.16	(0.50)	0.10	7.40	7.67	14.

1. The above is an extract of the detailed format of Quarterly Financial Results filed with Stock Exchanges under Regulation 33 of the SEBI (Listing and Other) Disclosure Requirements) Regulations 2015. The full format of the Financial Results are available on the Bombay Stock Exchange website (URL: www.bseindia. com/corporates), the National Stock Exchange website (URL: www.nseindia.com/corporates) and on the Company's website (URL: www.ramcoindltd.com).

Key informations on Standalone Un-audited Financial Results:								
		Quarter Ended		Nine Mon	Year Ended			
Particulars	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023		
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited		
Income from Operations	26,993	26,430	28,371	98,739	99,996	1,31,006		
Net Profit / (Loss) for the period (after tax, after Exceptional and / or Extraordinary items)	1,246	1,600	574	5,481	6,263	9,584		
Total Comprehensive Income for the period (Comprising Net Profit for the period after tax and other Comprehensive Income after tax)	1,267	3,795	1,370	7,709	6,886	10,321		
The previous period figures have been re-grouped / restated wherever considered necessary. For Ramco				Industries Limite	ed			

3. The previous period figures have been re-grouped / restated wherever considered necessary.

Managing Director DIN: 07273249 New Delhi

financialexp.epapr.in

Place: Gurugram

Date: 8 February 2024

08.02.2024

Chennai

in continuation of previous page....

- (y) Included an updated shareholding pattern of the Target Company as on the Identified Date along with relevant clarifications. Please refer to paragraph
- (z) Updated the list of documents available for inspection along with the details related to availability of electronic inspection of documents. Please refer to paragraph 10 of the LOF along with the updates to such disclosures pursuant to the Third Announcement and Corrigendum for further details.

Status of Statutory and Other Approvals

To the best of the knowledge of the Acquirer, as on the date of this Offer Opening Advertisement and Corrigendum, there are no statutory approvals required to acquire the Offer Shares that are validly tendered pursuant to this Offer and/ or to complete the Underlying Transactions. However, if any statutory or other approval(s) becomes applicable prior to the completion of the Offer, the Offer would also be subject to such statutory or other approval(s) being obtained and the Acquirer shall make necessary applications for such approvals. Please refer to paragraph 7.4 of the LOF for further details.

Revised Schedule of Activities:

Sr. No.	Activity	Schedule of activiti in the DLC		Revised schedule of activities ⁽¹⁾	
	N. O. S. W.	Date	Day	Date	Day
1.	Date of the PA	September 27, 2023	Wednesday	September 27, 2023	Wednesday
2.	Date of publication of the DPS	September 30, 2023	Saturday	September 30, 2023	Saturday
3.	Date of filing of the DLOF with SEBI	October 09, 2023	Monday	October 09, 2023	Monday
4.	Last date for the public announcement for competing offer(s)(2)	October 23, 2023	Monday	October 23, 2023	Monday
5.	Last date for receipt of SEBI observations on the DLOF (in the event SEBI has not sought clarifications or additional information from the Manager)	October 31, 2023	Tuesday	January 24, 2024 ⁽³⁾	Wednesday
6.	Identified Date ⁽⁴⁾	November 02, 2023	Thursday	January 29, 2024	Monday
7.	Last date by which the LOF is to be dispatched to the Eligible Shareholders whose names appear in the register of members on the Identified Date	November 09, 2023	Thursday	February 05, 2024	Monday
8.	Last date by which the committee of the independent directors of the Target Company is required to give its recommendation to the Eligible Shareholders for this Open Offer	November 15, 2023	Wednesday	February 08, 2024	Thursday
9.	Last date for upward revision of the Offer Price/ Offer Size	November 15, 2023	Wednesday	February 08, 2024	Thursday
10.	Date of publication of Offer opening public announcement in the newspapers in which the DPS has been published	November 16, 2023	Thursday	February 09, 2024	Friday
11.	Date of commencement of the Tendering Period ("Offer Opening Date")	November 17, 2023	Friday	February 12, 2024	Monday
12.	Date of closure of the Tendering Period ("Offer Closing Date")	December 01, 2023	Friday	February 26, 2024	Monday
13.	Last date of communicating the rejection/ acceptance and completion of payment of consideration or refund of Equity Shares to the Eligible Shareholders	December 15, 2023	Friday	March 12, 2024	Tuesday
14.	Last date for publication of post-Offer public announcement in the newspapers in which the DPS has been published	December 22, 2023	Friday	March 19, 2024	Tuesday

- (1) Where last dates are mentioned for certain activities, such activities may take place on or before the respective last dates.
- There is no competing offer as on the date of the LOF.
- Actual date of receipt of SEBI's final observations on the DLOF. The Identified Date is only for the purpose of determining the Eligible Shareholders as on such date to whom the LOF will be sent. It is clarified that all holders (registered or unregistered) of Equity Shares (except those who are excluded from the ambit of Eligible Shareholders) are eligible to participate in the Open Offer at any time during the Tendering Period.

विवरण

अपवादित मदा तथा कर पूर्व लाभ/(हानि)

कर पश्चात सामान्य क्रियाकलापों से शुद्ध लाभ/ (हानि)

कर पश्चात अवधि के लिए शुद्ध लाभ/(हानि)(असाधारण

प्रदत्त इक्विटी शेयर पूंजी (रु. 10/- प्रति का अंकित मूल्य)

आरक्षिति (पुनर्मुल्याकन आरक्षितों को छोड़कर) जैसा कि

आय प्रति शेयर (ईपीएस) (असाधारण मदों से पूर्व तथा

परिचालनों से कुल आय (शुद्ध)

तुलन पत्र में दर्शाया गया है

बाद) (रु. 10/- प्रति का)

मदों के बाद)

–तरल

8. Other Information:

8.1. The Acquirer and its directors in their capacity as directors, accept the responsibility for the information contained in this Offer Opening Advertisement and Corrigendum (except for the information pertaining to the Target Company and existing members of the promoter group of the Target Company, which has been compiled from information published or publicly available sources or provided by the Target Company) and also for the obligations of the Acquirer laid down in the SEBI (SAST) Regulations in respect of the Open Offer.

Issued by the Manager

8.2. This Offer Opening Advertisement and Corrigendum is expected to be available on SEBI's website at www.sebi.gov.in.

swastika

Swastika Investmart Limited

Registered Office: Flat No.18, 2nd Floor, North Wing, Madhaveshwar Co-operative Housing Society Ltd.

Madhav Nagar, 11/12, S. V. Road, Andheri W, Mumbai (MH) – 400058

Merchant Banking Division: 48 Jaora Compound, MYH Road, Indore (MP) – 452001

Contact person: Mohit Goyal Tel no.: +91 731 6644244; Fax no.: +91 731 6644300

Investor Grievance: mb.investorgrievance@swastika.co.in

Website: www.swastika.co.in SEBI registration: INM000012102 Validity period: Permanent

E-mail: merchantbanking@swastika.co.in

Registrar to the Offer

BEETAL

(राणि रुपये में

लेखापरीक्षित

28,016,968

8,133,980

6,086,397

99,475,000

6,086,397

45,236,144

हेल्पएज फिनलीज लिमिटेड

सिद्धार्थ गोयल

प्रबंध निदेशक

डीआईएन : 028551

0.61

BEETAL Financial & Computer Services Private Limited

Address: "BEETAL HOUSE", 3rd Floor, 99, Madangir, Behind Local Shopping Centre, New Delhi-110062

Tel. no.: 011-29961281-83,26051061, 26051064, Fax no.: 011-29961284

Email: beetal@beetalfinancial.com, beetalrta@gmail.com Website: www.beetalfinancial.com

SEBI registration: INR000000262 Validity period: Permanent

Contact person: Punit Kumar Mittal

Place: Thane (West) Date: February 08, 2024

अलेखापरीक्षित अलेखापरीक्षित

6,002,179

4,441,578

99,475,000

4,441,578

6,932,154 32,678,324 21,039,919

8,423,381

8,423,38

53,641,02

0.85 0.85

स्टैण्डएलोन

31.12.2023 30.09.2023 31.12.2022 31.12.2023 31.12.2022 31.03.2023

2,342,198 11,382,948

99,475,000 99,475,000

1,733,198

1,733,198

For and on behalf of the Acquirer Hella Infra Market Private Limited

पंजाब एण्ड सिंध बेंक जर्डा सेवा ही जीवन - ध्येथ है

होटल सम्राट हेवेन्स, मेरठ, उत्तर प्रदेश

कब्जा सूचना (अचल संपत्ति हेत्) (प्रतिभूति हित (प्रवर्तन) नियम, 2002 के नियम 8(1) के तहत)

जबकि अधोहस्ताक्षरी ने वित्तीय आस्तियों का प्रतिमृतिकरण और पुनर्गठन एवं प्रतिभृति हित प्रवर्तन अधिनियम 2002 (2002 का 54) के तहत पंजाब एण्ड सिंध बैंक, होटल सम्राट हेवेन्स. मेरठ, उत्तर प्रदेश का प्राधिकृत अधिकारी होने के नाते तथा प्रतिभृति हित (प्रवर्तन) नियम 2002 के नियम 3 के साथ पठित घारा 13(12) के तहत प्रदत्त शक्तियों का प्रयोग करते हुए उघारकर्ता / गारंटर श्री प्रतीक यादव पुत्र श्री प्रसाद यादव (उधारकर्ता) निवासी 210 नगला बहु जे.वी. अस्पताल के पास क्रिश्चियन कॉलोनी मेरठ साकेत, उत्तर प्रदेश - 250001 और श्रीमती पूनम यादव पत्नी श्री प्रसाद यादव (गारंटर / बंधककर्ता) निवासी 210 नगला बहु जे.वी. अस्पताल के पास क्रिश्चियन कॉलोनी मेरठ साकेत, उत्तर प्रदेश -250001 और श्री त्रिलोक चंद गुप्ता पुत्र श्री जगमोहम गुप्ता (गारंटर) निवासी 102/4 श्रद्धा पुरी फेस 2 मेरठ, उत्तर प्रदेश 250001 को मांग नोटिस दिनांक 07-11-2023 को जारी किया था, जिसमें सूचना में बकाया राशि रू. 12,42,287.77 (रु. बारह लाख ब्यालीस हजार दो सौ सत्तासी और पैसे सतहत्तर मात्र) और दिनांक 31.10.2023 तक ब्याज सहित और दिनांक 01.11.2023 से भविष्य का ब्याज एवं आकिस्मक प्रभार, इत्यादि सहित उक्त नोटिस की प्राप्ति की तिथि से 60 दिनों के अन्दर भुगतान करने को कहा गया था।

उधारकर्ता / गारंटर उक्त राशि का भुगतान करने में असफल हो गये हैं इसलिये एतद्द्वारा उधारकर्ता / गारंटर तथा सर्वसाधारण को सुचित किया जाता है कि अधोहस्ताक्षरी ने उक्त नियमों के नियम 8 के साथ पठित उक्त अधिनियम की धारा 13(4) के अधीन उन्हें प्रदत्त शक्तियों का इस्तेमाल करते हुए इसमें नीचे वर्णित सम्पत्ति का कब्जा दिनांक 07.02.2024 को ले

उधारकर्ता को विशेष रूप से और सर्वसाधारण को सामान्य रूप से चेतावनी दी जाती है कि वे निम्न सम्पत्ति के साथ लेन-देन न करें तथा सम्पत्ति के साथ कोई भी लेन-देन पंजाब एण्ड सिंध बैंक, शाखा कौशम्बी, के प्रभार वास्ते बकाया राशि रूरू. 12,42,287.77 (रु. बारह लाख ब्यालीस हजार दो सौ सत्तासी और पैसे सतहत्तर मात्र) और दिनांक 31.10.2023 तक और दिनांक 01.11.2023 से भविष्य का ब्याज एवं आकिस्मक प्रमार इत्यादि के अधीन होगा। वसुली घटाकर, यदि कोई हो

उधारकर्ता का ध्यान एक्ट की धारा 13 की उप धारा (8), के प्रावधानों के अंतर्गत सुरक्षित परिसंपत्तियों के मुक्त करने हेत् उपलब्ध समय सीमा की ओर आकर्षित किया जाता है। अचल सम्पत्ति का विवरण

सम्पत्ति का वह समस्त भाग एवं अंश जोकि मकान नं. 196(ओल्ड) वर्तमान नं. 440 का हिस्सा, क्षेत्रफल 51.13 वर्ग गज या 42.75 वर्ग मी., नगला बहु यादगारपुर मेरठ में स्थित, यह सम्पत्ति श्रीमती पूनम यादव पत्नी श्री प्रसाद यादव के नाम पर हैं।

1. मुल बिक्री विलेख उप-रजिस्ट्रार प्रथम, मेरठ बही नंबर 1, जिल्द नंबर 11620 पेज नंबर 19 से 48 पर क्रमांक 2856 दिनांक 05-05-2017 को पंजीकृत, सम्पत्ति चौहदी : उत्तर में -15 फीट 6 इंच / मकान की दीवार बिक्री के तहत, उसके बाद राम स्वरूप का मकान, दक्षिण में – 13 फीट 8 ½इंच / मकान का दरवाजा बिक्री के बाद रास्ता मुख्य नंगला बहु रोड, पूरब में - 34 फीट 2 इंच / मकान की दीवार बिक्री के तहत इसके बाद मकान का बाकी हिस्सा विक्रेता की बिक्री के तहत, पश्चिम में - 29 फीट 8 इंच / मकान की दीवार बिक्री के तहत, उसके बाद राजा का मकान

सेन्ट्रल बैंक ऑफ इंडिया

Central Bank of India

करोल बाग शाखा, 4/54, सर सोरबजी भवन, देश बंधु गुप्ता रोड, नई दिल्ली-110005

कब्जा सूचना (अचल सम्पत्ति के लिए)

प्रतिभूति हित (प्रवर्तन) नियम, 2002 के नियम 8(1) के तहत

जबिक वित्तीय आस्तियों के प्रतिभूतिकरण और पुनर्निर्माण तथा प्रतिभूति हित

अधिनियम 2002 के अंतर्गत सेंट्रल बैंक ऑफ इंडिया, करोल बाग शाखा,

नई दिल्ली का प्राधिकृत अधिकारी होने के नाते तथा प्रतिभूति हित (प्रवर्तन)

नियम, 2002 के नियम 3 के साथ पढ़े जाने वाले अनुच्छेद 13(12) के अंतर्गत

प्रदत्त शक्तियों का उपयोग करते हुए अधोहस्ताक्षरी ने मांग सूचना दिनांक

30 / 05 / 2023 जारी की थी, जिसके द्वारा कर्जदार: श्री रंजीत सिंह

पुत्र अमरीक सिंह को सूचना में उल्लिखित कुल राशि रु.14,20,145.46

(चौदह लाख बीस हजार एक सौ पैंतालिस रूपये एवं छियालिस पैसे

मात्र) 30 / 05 / 2023 को उक्त सूचना की प्राप्ति की तारीख से 60 दिनों के

भीतर भूगतान की तारीख तक आकस्मिक खर्चों, लागतों, शुल्कों आदि के साथ

संविदात्मक दर पर अर्जित ब्याज / अप्राप्त ब्याज के साथ चुकाने के लिए कहा

गया था। कर्जदार / गारंटर के इस राशि को चुकाने में असफल रहने के

कारण, कर्जदार / गारंटर तथा आम जनता को एतदद्वारा सूचित किया जाता है

कि अधोहस्ताक्षरी ने प्रतिभृति हित (प्रवर्तन) नियम, 2002 के नियम 8 के साथ

पढ़े जाने वाले कथित अधिनियम की धारा 13 की उप-धारा (4) के तहत प्रदत्त

शक्तियों का उपयोग करते हुए नीचे वर्णित सम्पत्ति का कब्जा 07 फरवरी

2024 को ले लिया है। कर्जदार / गारंटर को विशेष तौर पर तथा आम जनता

को सामान्य तौर पर एतदद्वारा सावधान किया जाता है कि वे सम्पत्ति के साथ

किसी प्रकार का लेन-देन न करें और सम्पत्ति का कोई भी लेनदेन रु.

14,20,145.46 (चौदह लाख बीस हजार एक सौ पैंतालिस रूपये एवं

छियालिस पैसे मात्र) 30 / 05 / 2023 को बँक को अंतिम भुगतान की तारीख

तक आकस्मिक खर्चों, लागतों, शुल्कों आदि के साथ संविदात्मक दर पर अर्जित

व्याज / अप्राप्त व्याज के साथ सेंट्रल बैंक ऑफ इंडिया, करोल बाग शाखा,

कर्जदार का ध्यान सुरक्षित सम्पत्ति को छुड़ाने के लिए उपलब्ध समय

के संबंध में अधिनियम के अनुच्छेद (13) के उप-अनुच्छेद (8) के

अचल सम्पत्तियों का विवरण

सम्पत्ति के सभी भाग एवं हिस्से फ्लैट नम्बर 20, चौथी मंजिल, ब्लॉक

नम्बर एफ-८, सेक्टर जी-८, नरेला, पॉकेट, दिल्ली। पुस्तक संख्या 1,

खंड क्रमांक 7464 में पंजीकरण संख्या 18, 121 वाले कन्वेयंस डीड के

माध्यम से पंजीकृत दिनांक 28/11/2019 को पृष्ठ 122 से 124 पर।

"IMPORTANT"

(प्राधिकृत अधिकारी) सेंट्रल बैंक ऑफ इंडिया,

करोल बाग शाखा, देश बंधु गुप्ता रोड, नई दिल्ली

नई दिल्ली के प्रभार के भुगतान के अधीन होगा।

प्रावधानों की ओर आकर्षित किया जाता है।

तिथि: 07/02/2024

स्थानः दिल्ली

दिनांक 07.02.2024, स्थान : मेरठ

प्राधिकृत अधिकारी, पंजाब एण्ड सिंध बैंक



साथ ही कंपनी की वेबसाईट www.helpagefinlease.com पर भी उपलब्ध है।

गई तथा 08.02.2024 को आयोजित उनकी बैठक में निदेशक मंडल द्वारा अनुमोदित किए गए।

≅medanta ग्लोबल हेल्थ लिमिटेड

हेल्पएज फिनलीज लिमिटेड

पंजी. कार्यालयः एस-191 सी, 3रा तल, मानक कॉम्प्लैक्स, स्कूल ब्लॉक, शकरपुर, दिल्ली-110092

सीआईएन : L51909DL1982PLC014434, वेबसाइट : www.helpagefinlease.com

दूरभाष नं. : +91-11-22481711, फैक्स नं. : +91-11-22481711

31 दिसम्बर, 2023 को समाप्त तिमाही तथा नौमाही के अनंकेक्षित स्टैंडएलॉन वित्तीय परिणामों का विवरण

12,776,928 13,397,724

99,475,000 99,475,000

4,084,745

4,084,745

3,220,575

3,220,575

0.32 0.32

1) उपरोक्त सेबी (सुचीयन दायित्व तथा उद्घाटन अपेक्षा) विनियमन, 2015 के विनियमन 33 के अंतर्गत स्टॉक एक्सचैंजों में दाखिल की गई तिमाही वित्तीय

2) 31 दिसम्बर, 2023 को समाप्त तिमाही तथा नौमाही के लिए कंपनी के उपरोक्त अनंकेक्षित स्टैंडएलॉन वित्तीय परिणामों की ऑडिट किमटी द्वारा समीक्षा की

परिणामों के विस्तृत प्रारूप का सार है। तिमाही वित्तीय परिणामों का संपूर्ण प्रारूप स्टॉक एक्सचेंज की वेबसाईट अर्थात् (www.bseindia.com) तथ

सीआईएन: L85110DL2004PLC128319 रिज. कार्यालय: मेदांता मेडिक्लिनिक, ई-18, डिफेंस कॉलोनी, नई दिल्ली 110024, भारत कापोरेंट कार्यालय: मेदांता-द मेडिसिटी, सेक्टर -38, गुरुग्राम, हरियाणा 122001, भारत दूरभाषः+91 124 483 4060 | ई-मेलः compliance@medanta.org | वेबसाइटः https://www.medanta.org

(पूर्व का ग्लोबल हेल्थ प्राइवेट लिमिटेड)

31 दिसम्बर, 2023 को समाप्त तिमाही तथा नौमाही के लिए समेकित अलेखापरीक्षित वित्तीय परिणामों का सार (ईपीएस को छोड़कर लाख रुपये में)

क्र. सं.	विवरण	समाप्त तिमाही 31.12.2023	समाप्त नौमाही 31.12.2023	समाप्त वर्ष 31.12.2022
		(अलेखापरीक्षित)	(लेखापरीक्षित)	(अलेखापरीक्षित
1	प्रचालनों से कुल आय	85,453.28	251,372.12	70,622.60
2	अवधि हेतु निवल लाभ (कर तथा अपवादित मदों से पूर्व)	17,236.47	48,401.08	11,244.94
3	कर पूर्व अवधि हेतु निवल लाभ (अपवादित मदीं के बाद)	17,236.47	48,401.08	11,244.94
4	कर पश्चात अवधि हेतु निवल लाभ (अपवादित मदों के पश्चात)	12,354.07	35,071.18	8,061.38
5	अवधि हेतु कुल व्यापक आय [अवधि हेतु (कर पश्चात) लाभ तथा अन्य व्यापक आय (कर पश्चात) शामिल]	12,406.07	34,978.22	8,087.52
6	प्रदत्त इक्विटी शेयर पूंजी	5,368.55	5,368.55	5,363.70
7	आरक्षितियां (पुनर्मूल्यांकन आरक्षितियों को छोड़कर)*			100400000000000000000000000000000000000
8	आय प्रति शेयर (रु. 2/- प्रत्येक) बेसिक डाइल्यूटेड	4.61 4.60	13.07 13.06	3.08 3.08

* 31 मार्च 2023 को आरक्षिति (पुनर्मुल्यांकन आरक्षिति को छोड़कर) 2,37,456.92 लाख रुपये था। 31 दिसम्बर, 2023 को समाप्त तिमाही तथा नौमाही के

लिए स्टैण्डएलोन अलेखापरीक्षित वित्तीय परिणामों का सार

(रु. लाख में) क्र. तिमाही वर्ष नौमाही 31.12.2022 31.12.2023 31.12.2023 (लेखापरीक्षित) अलेखापरीक्षित (अलेखापरीक्षित) प्रचालनों से कुल आय 177,168.33 50,230.89 58,751.10 अवधि हेतु निवल लाभ (कर तथा अपवादित मदों से पूर्व) 12,087.21 36,350.32 7,989.37 कर पूर्व अविध हेतु निवल लाभ (अपवादित मदों के बाद) 12,087.21 36,350.32 7,989.37 🛕 कर पश्चात अवधि हेतु निवल लाभ (अपवादित मदों के पश्चात) 5,877.26 8,734.40 26,865.15 अवधि हेतु कुल व्यापक आय [अवधि हेतु (कर पश्चात) लाभ तथा अन्य व्यापक आय (कर पश्चात) शामिल] 8,777.17 26,760.24 5,893.01 नोट :

1. लेखापरीक्षा समिति द्वारा इन परिणामों की समीक्षा और सिफारिश की गई है और तदनुसार 8 फरवरी, 2024 को आयोजित उनकी संबंधित बैठकों में कंपनी के निदेशक मंडल द्वारा अनुमोदित किया गया है। ये परिणाम कंपनी के सांविधिक लेखा परीक्षकों की सीमित समीक्षा के अध्यधीन हैं।

2. उपरोक्त सेबी (सूचीबद्धता दायित्व और प्रकटन अपेक्षाएं) विनियम, 2015 के विनियम 33 के तहत स्टॉक एक्सचेंजों के साथ दाखिल किए गए वित्तीय परिणामों के विस्तृत प्रारूप का उद्धरण है। समेकित और स्टैंडअलोन तिमाही/वार्षिक वित्तीय परिणामों का पूर्ण प्रारूप स्टॉक एक्सचेंज की वेबसाइटों (www.bseindia.com और www.nseindia.com) पर तथा कंपनी की वेबसाइट https://www.medanta.org पर भी उपलब्ध है।

बोर्ड की आज्ञानुसार ग्लोबल हेल्थ लिमिटेड के लिए

स्थानः गुरुग्राम दिनांक: 8 फरवरी, 2024

हस्ता./-डॉ. नरेश त्रेहन अध्यक्ष एवं प्रबंध निदेशक

रामसन्स प्रोजेक्ट्स लिमिटेड सीआइएन : L74899DL1994PLC063708

पंजीकृत कार्यालय: 201, एम्पायर अपार्टमेंट, प्रथम तल, सुल्तानपुर, एम.जी. रोड, गदाईपुर, साउथ वेस्ट दिल्ली - 110030, नई दिल्ली

कॉर्परिट कार्यालय: यूनिट 501, 5वीं मंजिल, एसएएस टावर, टावर बी, सेक्टर-38, गुरुग्राम - 122001, हरियाणा

वेबसाइट : www.ramsonsprojects.com, ई-मेल: corprelations@ramsonsprojects.com 31 दिसंबर, 2023 को समाप्त तिमाही और नौमाही के लिए स्टैंडअलोन अन-ऑडिटेड वित्तीय परिणामों का विवरण

(आंकड़े लाख में)

क्र. सं.	विवरण	तिमाही समाप्त 31/12/2023 (अलेखापरीक्षित)	तिमाही समाप्त 31/12/2022 (अलेखापरीक्षित)	नौमाही समाप्त 31/12/2023 (अलेखापरीक्षित)
1	प्रचालनों से कुल आय	11.18	15.05	35.46
2	अवधि हेतु शुद्ध लाभ / (हानि) (कर, अपवादात्मक तथा/अथवा असाधारण मदों से पूर्व)	0.34	0.56	6.99
3	अवधि हेतु शुद्ध लाभ / (हानि) कर से पहले (अपवादात्मक तथा / अथवा असाधारण मदों के पश्चात)	0.34	0.56	6.99
4	अवधि हेतु शुद्ध लाभ / (हानि) कर पश्चात (अपवादात्मक तथा / अथवा असाधारण मदों के पश्चात)	0.30	0.58	6.18
5	अवधि हेतु कुल समावेशी आय [जिसमें अवधि हेतु लाभ / (हानि) (कर पश्चात) तथा अन्य समावेशी आय (कर पश्चात) सिम्मिलित है]	3.06	0.94	(226.26)
6	इक्विटी शेयर पूंजी	300.65	300.65	300.65
7	पिछले वर्ष की लेखापरीक्षित तुलन पत्र में दर्शाए अनुसार आरक्षित निधि (पुनर्मूल्यांकन आरक्षित निधि को छोड़कर)	-	-	-
8	अर्जन प्रति शेयर (रू. 10/- प्रत्येक का) (जारी और बंद प्रचालनों हेतु)*			
S	1 मूल :	0.01	0.02	0.21
	2 तनुकृत :	0.01	0.02	0.21
नोट्र	T :	1. 1.		

- *अंतरिम अवधि के लिए प्रति शेयर आय वार्षिक नहीं है।
- 31 दिसंबर, 2023 को समाप्त तिमाही और नौमाही के लिए कंपनी के वित्तीय परिणाम स्टैंडअलोन आधार पर तैयार किए गए हैं, क्योंकि ऐसी कोई स्थिति नहीं है जहां कंपनी के मामले में समेकन की आवश्यकता होती है। जहां भी आवश्यक हो, संबंधित अवधियों के आंकड़ों को पुनर्समूहित और पुनर्व्यवस्थित किया गया है-
- उपरोक्त सेबी (लिस्टिंग दायित्व और प्रकटीकरण आवश्यकता) विनियमन 2015 के विनियमन 33 के तहत स्टॉक एक्सचेंज में दायर तीमाही और नौमाही
- वित्तीय परिणामों का एक सारांश है। तिमाही और नौमाही परिणामों का पूरा प्रारूप स्टॉक एक्सचेंज की वेबसाइट (www.bseindia.com) और कंपनी की वेबसाइट (www.ramsonsprojects.com) पर उपलब्ध है।

बोर्ड के आदेश द्वारा रामसन्स प्रोजेक्ट्स लिमिटेड प्रबंध निदेशक

डीआईएन: 00012115

स्थान: गुरुग्राम, हरियाणा तिथि: 7 फरवरी. 2024

Date: February 08, 2024

Place: Mumbai

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of offer dated 09th January, 2024 the "Letter of Offer" or ("LOF") filed with the BSE Limited ("BSE") and the Securities and Exchange Board of India ("SEBI").



Our Company was originally incorporated as "Adi Rasayan Limited" a private limited company vide a Certificate of Incorporation dated 16th November, 1992, issued by the Registrar of Companies, Gujrat, Dadra & Nagar Haveli under the provisions of the Companies Act, 1956. Subsequently, the name of our Company was changed to "Generic Pharmasec Limited" and a fresh certificate of incorporation dated 27th November, 2018 consequent upon change of name was issued by the Registran of Companies, Ahmedabad. Thereafter, the name of our Company was further changed to "Genpharmasec Limited" and a fresh certificate of incorporation dated 25th October, 2021 consequent upon change of name was issued by the Registrar of Companies, Mumbai. For further details in relation to our Company, please refer to the section titled "General Information" beginning on page 50 of this Letter of offer.

Registered Office: Office No. 104 & 105 1st Floor, Gundecha Industrial Premises Co-op Soc. Ltd., Akurli Road, Kandivali East, Mumbai City MH - 400101 | Tel: No. +91-86555 50242

E-mail: compliance@genpharmasec.com | Website: www.genpharmasec.com

Contact Person: Ms. Heta Deepak Shah, Company Secretary & Compliance Officer

PROMOTERS OF OUR COMPANY: MR. RAJESH SADHWANI AND MRS. SNEHA SADHWANI THE ISSUE

ISSUE OF UPTO 27,68,59,850 EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH ("EQUITY SHARES") OF GENPHARMASEC LIMITED ("GENPHARMA" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 1.75 PER EQUITY SHARE (INCLUDING PREMIUM OF ₹ 0.75 PER EQUITY SHARE) ("ISSUE PRICE") FOR AN AGGREGATE AMOUNT NOT EXCEEDING ₹ 4.845.05 LAKHS TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE. I.E. TUESDAY, 09™ JANUARY, 2024 (THE "ISSUE"). THE ISSUE PRICE IS 1.75 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 123 OF THE LETTER OF OFFER. ATTENTION INVESTORS

NOTICE TO THE READER ("NOTICE") — CORRIGENDUM CUM ADDENDUM TO LETTER OF OFFER DATED JANUARY 09, 2024 AND CORRIGENDUM CUM ADDENDUM DATED JANUARY 20, 2024

This notice should be read in conjunction with the LOF and Corrigendum cum addendum to Letter of Offer dated January 09. 2024 and Corrigendum cum addendum dated January 20, 2024 filed by the Company with the Stock Exchange and SEBI and the ALOF and CAF that have been sent to the Eligible Equity Shareholders of the Company. The Eligible Equity Shareholders are requested to please note the following:

RIGHTS ISSUE PERIOD EXTENDED

THE TOOL T	
ISSUE CLOSING DATE (OLD)	ISSUE CLOSING DATE (NEW)
FRIDAY, 09™ FEBRUARY, 2024	TUESDAY, 13™ FEBRUARY, 2024
	that the date of closure of the Rights Issue, which opened on day. February 09, 2024 has now been extended from Friday.

February 09, 2024 to Tuesday, February 13, 2024, by the Rights Issue Committee in its Meeting held on February 08, 2024 in order to provide an opportunity to shareholders to exercise their rights in the Rights Issue. Accordingly, the last date of submission of the duly filled in CAF (along with the amount payable on application) is Tuesday,

February 13, 2024. Equity Shareholders of the Company who are entitled to apply for the Rights Issue as mentioned above are requested to take note of the Issue Closure Date as Tuesday, February 13, 2024. This Corrigendum cum addendum shall be available on the respective websites of the Stock Exchange at www.bseindia.com

and the website of the Company at www.genpharmasec.com Accordingly, there is no change in the LOF, CAF and ALOF dated January 09, 2024 except for modification in the Issue Closing

date. Change in Issue closing date resultant change in indicative time table of post issue activities on account of extension of issue closing date.

INVESTORS MAY PLEASE NOTE THE LETTER OF OFFER, ABRIDGED LETTER OF OFFER, COMMON APPLICATION FORM. CORRIGENDUM CUM ADDENDUM TO LETTER OF OFFER DATED JANUARY 20, 2024 SHALL BE READ IN CONJUCTION WITH THIS CORRIGENDUM CUM ADDENDUM.

For Genpharmasec Limited

On Behalf of the Board of Directors

Ms. Heta Deepak Shah

Company Secretary and Compliance officer

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer dated January 09, 2024 with the Securities and Exchange Board of India and BSE. The Letter of Offer is available on the website of SEBI at www.sebi.gov.in, website of Stock Exchange where the Equity Shares are listed i.e., BSE at www.bseindia.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 31 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.















